论文部分内容阅读
目的:观察补肾敛肺颗粒联合噻托溴铵防治慢性阻塞性肺疾病急性加重(AECOPD)的临床疗效。方法:选稳定期慢性阻塞性肺疾病(COPD)患者随机分治疗组75例,对照组74例。治疗组口服补肾敛肺颗粒,同时联合吸入噻托溴铵粉雾剂,连续应用12个月。对照组单纯给予吸入噻托溴铵粉雾剂。记录12个月中AECOPD次数以及住院治疗的次数;治疗前、治疗结束时测量第一秒用力呼气容积(FEV1)及FEV1占预计值,并采用圣·乔治呼吸问卷(中文版)进行生活质量评分。结果:治疗组1年中首次急性加重时间较对照组显著延长,治疗组1年中平均急性加重的次数、住院次数较对照组显著减少,治疗组治疗结束时肺功能、生活质量评估优于对照组,差异均有统计学意义(P<0.05)。结论:补肾敛肺颗粒联合噻托溴铵能显著减少COPD患者急性加重及住院次数,显著改善患者肺功能及生活质量。
Objective: To observe the clinical efficacy of “Bushenyongfei” combined with tiotropium in prevention and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 75 patients with stable COPD (chronic obstructive pulmonary disease) were randomly divided into treatment group (n = 74) and control group (n = 74). The treatment group oral Buke convergence lung particles, while inhaled tiotropium bromide powder, continuous application of 12 months. The control group was given inhaled tiotropium bromide powder. Record the number of AECOPD in 12 months and the number of hospitalizations; before treatment, the first second forced expiratory volume (FEV1) and FEV1 were measured at the end of treatment, and the quality of life was measured by St. George’s Respiratory Questionnaire (Chinese version) score. Results: The first acute exacerbation time in the treatment group was significantly longer than that in the control group in one year. The average number of acute exacerbations and the number of hospitalizations in the treatment group decreased significantly compared with the control group in one year. The pulmonary function and quality of life in the treatment group were better than those in the control group Group, the difference was statistically significant (P <0.05). Conclusion: Bushenyongfei granule combined with Tiotropium can significantly reduce acute exacerbations and hospitalizations of patients with COPD and significantly improve pulmonary function and quality of life.